Antipsychotic‐Induced Hyperprolactinemia by Bostwick, Jolene R. et al.
Antipsychotic-Induced Hyperprolactinemia
Jolene R. Bostwick, Pharm.D., Sally K. Guthrie, Pharm.D., FCCP, and
Vicki L. Ellingrod, Pharm.D., FCCP
Use of antipsychotic agents has been associated with hyperprolactinemia, or
elevated prolactin levels; this hormonal abnormality can interfere with the
functioning of reproductive, endocrine, and metabolic systems. As
antipsychotic agents are increasingly used for both United States Food and
Drug Administration–approved and nonapproved indications, many
individuals are at risk for developing antipsychotic-induced hyperprolactinemia.
First-generation antipsychotics pose the greatest risk of causing this adverse
effect; however, second-generation antipsychotics, particularly risperidone
and paliperidone, also often increase prolactin secretion. Hyperprolactinemia
has short- and long-term consequences that can seriously affect quality of life:
menstrual disturbances, galactorrhea, sexual dysfunction, gynecomastia,
infertility, decreased bone mineral density, and breast cancer. Although many
of these are definitively connected to elevated prolactin levels, some, such as
breast cancer, require further study. Both clinicians and patients should be
aware of hyperprolactinemia-associated effects. To prevent or alleviate the
condition, tailoring an antipsychotic drug regimen to each individual patient
is essential. In addition, the risk of hyperprolactinemia can be minimized by
using the lowest effective dose of the antipsychotic agent. If the effects of
prolactin are evident, the drug can be changed to another agent that is less
likely to affect prolactin levels; alternatively, a dopamine agonist may be
added, although this may compromise antipsychotic efficacy. Additional
research is needed to clarify the appropriate level of monitoring, the long-term
effects, and the optimal treatment of antipsychotic-induced hyperprolactinemia.
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Antipsychotic Drug Selection and Management of the
Effects of Hyperprolactinemia
Conclusion
Use of antipsychotic agents has been associated
with hyperprolactinemia, or elevated prolactin
levels. Hyperprolactinemia is more than an
abnormal laboratory value; elevated prolactin
levels can interfere with the functioning of
reproductive, endocrine, and metabolic systems.
When first-generation antipsychotics were the
only treatment available for psychosis, hyper-
prolactinemia from use of these agents was
recognized but often ignored. All of the first-
generation antipsychotics caused hyperprolactinemia,
and elevated prolactin levels were generally
accepted as both inevitable and preferable to
untreated psychosis. With the advent of atypical
or second-generation antipsychotics, clinical
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monitoring and identification of the conse-
quences of hyperprolactinemia have received
greater recognition because these agents can offer
a differential profile of adverse effects and some
of the newer agents cause little to no elevation of
prolactin levels. Recent research has provided a
more comprehensive understanding of the many
functions of prolactin that result in the
multifactorial effects of hyperprolactinemia.
Prolactin
Prolactin is a polypeptide hormone that
contains 199 amino acids and is categorized as
part of the growth hormone family.1 It is secreted
primarily by lactotroph cells located in the
anterior pituitary. Prolactin also is produced in
other locations such as adipose cells in subcu-
taneous, breast, and visceral tissues. Although
the best known actions of prolactin relate to
reproduction, pregnancy, and lactation, the
hormone appears to be involved in many more
functions than previously thought.2 Prolactin
binds to specific prolactin receptors that belong
to the class I cytokine receptor family and are
present in organs such as the pancreas, liver,
uterus, and prostate.3 Binding at the prolactin
receptor results in activation of a variety of
signaling pathways that alter the transcription of
genes causing tissue changes.1, 2
Secretion of prolactin is pulsatile, with peaks
and troughs that follow a circadian cycle. Peak
secretion occurs nightly, approximately 4 hours
after sleep onset, and the nadir occurs in the
morning, approximately 6 hours after waking. In
addition to circadian peaks, prolactin levels are
transiently elevated by meals, stress, and sexual
activity. Regulation is complex, with serotonin
(through 5-HT1A and 5-HT2 receptors) causing
stimulation of prolactin release and estrogen
causing increased production of prolactin. However,
the major regulation of pituitary prolactin secretion
is largely inhibitory.4 Dopamine, which is released
by tuberoinfundibular neurons, normally acts at
D2 receptors on lactotropes to tonically inhibit
prolactin secretion and maintain physiologically
normal prolactin levels in the blood. The Taq1 A
polymorphism of the D2-receptor gene may play
a role in the strength of dopamine-mediated
inhibition of prolactin secretion. Carriers of the
less frequent A1 allele have a lower density of D2
receptors in the striatum, which can lead to a
dopamine deficiency through higher D2
occupancy, increasing the risk for antipsychotic-
induced hyperprolactinemia.5–7 This may be
particularly important for female patients with
the A1 allele, who appear to be at an increased
risk for developing antipsychotic-induced
hyperprolactinemia.5, 8
Because of the complex regulation of prolactin
release, a variety of drugs have been associated with
hyperprolactinemia, such as antidepressants (tri-
and tetracyclic antidepressants, monoamine oxidase
inhibitors, serotonin-specific reuptake inhibitors),
gastrointestinal drugs (metoclopramide, domperi-
done), antihypertensives (methyldopa, verapamil,
reserpine), some serotonergic drugs, antiandrogens,
estrogens, opiates, and cocaine.9, 10 Patients taking
these drugs, particularly if used in combination with
antipsychotic agents, may be at an increased risk for
drug-induced hyperprolactinemia.
Physiologic Effects of Hyperprolactinemia
Any individual taking a drug that blocks the
inhibition of prolactin secretion is at risk for the
development of hyperprolactinemia; however,
specific populations such as children, adolescents,
premenopausal women, and women in the
perinatal period are at higher risk.1 During
pregnancy, the secretion of prolactin levels is
elevated 10–20 times the nonpregnant value,
resulting in breast enlargement and milk
production, as well as decreases in libido and
fertility. Prolactin also affects actions of other
hormones and enzymes in a variety of tissues.
For instance, in hepatocytes, prolactin activates a
cotransporting peptide for sodium-taurocholate;
in T lymphocytes, prolactin promotes production
of interferon-regulatory factor 1; and in
reproductive tissue, it induces transcription of
the estrogen receptor and 3-hydroxysteroid
dehydrogenase.3 Prolactin not only is produced
within adipose tissues but also may have a
regulatory function in the tissue, although that
exact function has not yet been determined.
Since prolactin has some of its strongest effects
on the reproductive system, it is not surprising
that a supraphysiologic elevation of prolactin
level should affect the reproductive organs.
Drug-induced hyperprolactinemia, resulting in
elevations of prolactin level 2–4 times the upper
limit of the normal range of 15–25 µg/L in men
and women, causes significant effects on the
reproductive system. Elevated prolactin levels
can affect sex hormone dysfunction by inhibiting
the release of hypothalamic gonadotropin-
releasing hormone.11 Once gonadotropin-
releasing hormone is inhibited, release of
luteinizing hormone and follicle-stimulating
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hormone from the pituitary is also inhibited.
The inhibition of luteinizing hormone and
follicle-stimulating hormone by elevated
prolactin levels occurs in both men and women,
resulting in reduced testosterone and estrogen
production that can lead to widespread
consequences.12
Short-term concerns associated with hyper-
prolactinemia include menstrual disturbances,
galactorrhea, sexual dysfunction, and infertility
in women, as well as sexual dysfunction and
gynecomastia in men.1, 13 Galactorrhea can occur
in both sexes, but it is more common in women
and may occur in up to 57% of those experi-
encing elevated prolactin levels.14, 15 Gynecomastia,
however, is fairly uncommon.11
Prolonged hyperprolactinemia through
estrogen deficiency in women and testosterone
deficiency in men may result in decreased bone
mineral density (BMD) in both men and
women.13, 15–17 This can be especially concerning
in younger patients treated with prolactin-
elevating drugs who have not yet achieved peak
BMD.18
Finally, another potential long-term effect of
hyperprolactinemia is breast cancer in women.13
This longstanding debate was spurred by the
finding that prolactin plays a key role in the
development of mammary tumors in mice and
rats.19 In the 1970s, some clinicians recommended
against the use of drugs that can lead to
hyperprolactinemia in patients with this disease
or if breast cancer is suspected.20, 21 The debate of




The prevalence of hyperprolactinemia secondary
to the use of an individual antipsychotic is
roughly equated to the potency of its ability to
block D2 receptors. The first-generation anti-
psychotics are generally associated with greater
risks of prolactin level elevation compared with
second-generation antipsychotics, with the
exception of risperidone and paliperidone.12, 22, 23
When the second-generation antipsychotics
were initially marketed, there was widespread
hope that many of the adverse effects that had
been problematic with first-generation anti-
psychotics, such as anticholinergic effects, short-
and long-term extrapyramidal movement
disorders, and possibly the effects of hyper-
prolactinemia, would become concerns of the
past. Although the second-generation anti-
psychotics do generally cause less anticholinergic
load and fewer extrapyramidal symptoms, they
may have a propensity to cause hyperglycemia,
hyperlipidemia, and weight gain. In addition, the
landmark Clinical Antipsychotic Trials of Inter-
vention Effectiveness (CATIE) study demonstrated
that the efficacy of perphenazine (a first-
generation antipsychotic) was comparable to that
of many second-generation antipsychotics.24 The
burden of adverse events was also comparable,
although the actual frequency of specific adverse
events differed among the antipsychotics
evaluated. Since first-generation antipsychotics
are less expensive than second-generation
antipsychotics, this may provide clinicians with a
reason to again consider prescribing first-
generation antipsychotics, increasing the risk of
hyperprolactinemia and its consequences.
The frequency of antipsychotic-induced hyper-
prolactinemia varies, depending on the anti-
psychotic agent prescribed. Although some of
the second-generation antipsychotics, such as
olanzapine, quetiapine, ziprasidone, aripiprazole,
and clozapine, lack significant effects on prolactin,14
antipsychotic-induced hyperprolactinemia in
patients who are treated with first-generation
antipsychotics and risperidone is highly
prevalent.12 The prevalence of hyperprolactinemia
was evaluated in 402 patients taking first-
generation antipsychotics or risperidone in
average daily doses of 4.2–5.2 mg.12 This open-
label study found that 65.6% of women of
reproductive age, 45.1% of postmenopausal
women, and 42.4% of men experienced
antipsychotic-induced hyperprolactinemia.
Results from clinical trials of children and
adolescents treated with risperidone showed an
elevation of prolactin levels in 82–87% of
patients compared with 3–7% of those treated
with placebo.22 Paliperidone caused elevations in
prolactin levels that were comparable to those
seen with risperidone, in both children and
adults, which is not unexpected since paliperi-
done is the primary metabolite of risperidone.23
Although hyperprolactinemia is more likely to
occur with first-generation antipsychotics and
the second-generation agents risperidone and
paliperidone, the extent of prolactin level
increase shows great inter- and intraindividual
variability (Table 125–33).1 However, when
patients are treated with higher doses of these
agents, women (especially of reproductive age)
and younger patients exhibit the greatest risk for
hyperprolactinemia.4, 12, 34
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Consequences
Antipsychotic agents are used for both United
States Food and Drug Administration (FDA)–
approved and nonapproved indications in both
adults and children, including schizophrenia,
bipolar disorder, schizoaffective disease, the
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Table 1. Studies That Measured Prolactin Levels in Patients Receiving Antipsychotic Drugs
Study Drugs (no. of patients) Study Description Prolactin Effects
Chlorpromazine, haloperidol, Patients with schizophrenia were drug After 3 wks of therapy, mean ± SD prolactin
trifluoperazine, fluphenazine free for ≥ 8 wks, then treated with level was 39.65 ± 27.91 ng/ml vs
decanoate first-generation antipsychotics for up 8.29 ± 5.1 ng/ml at baseline in men (p<0.05),
(n=109; 67 male, 42 female)25 to 6 wks; number of patients receiving and 102.54 ± 66.03 ng/ml vs 10.74 ± 8.1
each drug not specified; mean doses ng/ml at baseline in women (p<0.05)
were 653 mg/day in men and 349 mg/day
in womena
Flupenthixol decanoate, Patients with schizophrenia were treated Mean ± SD prolactin level was 404 ± 419.5
haloperidol decanoate, for ≥ 2 yrs with first-generation mIU/L in men vs 1061.3 ± 629 mIU/L in
oral haloperidol, pimozide, antipsychotics; number of patients women (p<0.001); 16 men (34%) and
fluphenazine, sulpiride, receiving each drug not specified; 15 women (75%) had levels above upper
zuclopenthixol, droperidol, women had to be premenopausal; limit of normal (normal < 480 mIU/L)
chlorpromazine mean ± SD doses were 199.0 ± 220.1
(n=67; 47 male, 20 female)26 mg/day in men and 384.4 ± 302.5
mg/day in women,a p<0.05
Risperidone, olanzapine Patients with schizophrenia had Mean ± SD prolactin level was 132.2 ± 59.1
(n=20; all female)27 menstrual disorders, galactorrhea, or ng/ml after ≥ 4 wks of risperidone vs
sexual dysfunction; patients were 23.4 ± 22.7 ng/ml after 8 wks of olanzapine
receiving risperidone (mean ± SD dose (p<0.01)
3.5 ± 1.2 mg/day), then switched to
olanzapine (mean ± SD dose 9.1 ± 1.8
mg/day) for 8 wks
Paliperidone 6-wk, multicenter, double-blind, At 6 wks, mean ± SD prolactin level in
(n=374; 202 male, 172 female), randomized, placebo-controlled trial paliperidone group was 45.3 ± 23.2 ng/ml
olanzapine in patients with schizophrenia; vs 17.4 ± 19.9 ng/ml at baseline in men,
(n=128; 60 male, 68 female), previous therapy stopped for ≥ 3 days; and 124.5 ± 65.5 ng/ml vs 38.0 ng/ml at
placebo patients assigned to paliperidone baseline in women; mean prolactin level
(n=126; 66 male, 60 female)28 6 mg/day (n=123), 9 mg/day (n=122), decreased from baseline in those receiving
or 12 mg/day (n=129); olanzapine olanzapine or placebo (no statistical
10 mg/day; or placebo analyses were reported)
Olanzapine 6-wk, double-blind, placebo-controlled Actual prolactin levels not reported;
(n=198; 170 male, 28 female), study in patients with schizophrenia; however, at 2, 4, and 6 wks, levels were
haloperidol patients assigned to olanzapine 5 mg above normal in both men and women
(n=69; 62 male, 7 female), (n=65), 10 mg (n=64), or 15 mg receiving haloperidol (p<0.001), whereas
placebo (n=69); haloperidol 15 mg; or placebo; olanzapine caused slight increase above
(n=68; 62 male, 6 female)29 prolactin levels measured at baseline, normal only in women; prolactin level
and after 2, 4, and 6 wks of treatment did not increase with placebo at any time
point
Olanzapine (7 female), Patients with schizophrenia treated for Mean ± SD prolactin levels were 654 ± 456
clozapine (11 female), ≥ 12 wks with study drug, then mE/L in olanzapine group (p=0.005 vs
first-generation antipsychotics prolactin levels measured; first-generation antipsychotic group),
(31 female): flupenthixol antipsychotic dosages not reported 467 ± 170 mE/L in clozapine group
(n=12), perphenazine (n=4), (p<0.001 vs first-generation antipsychotic
haloperidol (n=5), perazine group), and 1600 ± 1278 mE/L in first-
(n=5), fluphenazine (n=5)30 generation antipsychotic group
(normal range 70–410 mE/L)
First-generation antipsychotics Combined analysis of three open-label After 6 wks of ziprasidone, mean ± SD
(n=108; 72 male, 36 female), studies in patients with schizophrenia prolactin levels decreased in the first-
olanzapine or schizoaffective disorder; at baseline, generation antipsychotic group
(n=104; 65 male, 39 female), patients switched from unreported (27.4 ± 28.1 ng/ml, p<0.05) and in the
risperidone dosages of olanzapine, risperidone, or risperidone group (51.0 ± 41.07 ng/ml,
(n=58; 40 male, 18 female); first-generation antipsychotics to p<0.0001); prolactin level did not change
all switched to ziprasidone31 ziprasidone; prolactin levels measured in the olanzapine group (15.2 ± 11.3 ng/ml)
at baseline and after 6 wks of
ziprasidone, mean dose 91 mg/day
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behavioral symptoms of dementia, treatment-
resistant depression, personality disorders, and
autism. With increased utilization, more patients,
including very young patients, are at risk for
developing hyperprolactinemia and its resulting
effects. Since the 1990s, children as young as 2
years have been exposed to antipsychotic drugs
at rates similar to that of adults, and utilization
has continued to increase in this demographic,
especially with second-generation antipsychotics.35, 36
Long-term consequences of using antipsychotic
agents in this population, including hyper-
prolactinemia, are unknown.
Menstrual Disturbances
One of the effects that appears most directly
related to hyperprolactinemia is menstrual
disturbance. A study of Indian women taking
first-generation antipsychotics found that the
frequency of menstrual disturbance was 54%,
amenorrhea 12%, and galactorrhea 32%.37 The
presence of galactorrhea was more likely in those
who had previously given birth. Other studies
have compared menstrual disturbances between
those taking first-generation and those taking
second-generation antipsychotics. In one study,
abnormal menstrual cycles were reported in 88%
of women treated with risperidone compared
with 48% of women taking first-generation
antipsychotics.12 In an 8-week comparison of
risperidone and olanzapine, 60% of females
taking risperidone and 25% of those taking
olanzapine reported amenorrhea at 8 weeks.27
An outpatient multicenter study based in Europe
calculated the odds ratio for amenorrhea and
galactorrhea when comparing a variety of
antipsychotics with olanzapine.38 The odds ratio
for amenorrhea with risperidone was 2.49,
quetiapine 0.75, clozapine 1.56, and oral first-
generation antipsychotics 1.06. Another
multicenter study, conducted in Spain, found that
the percentage of women experiencing amenorrhea
in those taking haloperidol was 14%, olanzapine
11%, quetiapine 5.6%, and risperidone 28.2%.39
Based on the overall results of these studies,
although the specific percentages vary, the risk of
developing menstrual disturbances secondary to
an antipsychotic appears to roughly parallel the
risk of developing hyperprolactinemia.
Sexual Dysfunction
Another consequence of hyperprolactinemia is
sexual dysfunction. However, evaluating effects
on sexual functioning is a rather difficult task
because so many different factors other than
pharmacology can affect sexual functioning.
Some data indicate that before any treatment
with antipsychotics, men with schizophrenia are
less likely to form sexual relationships than men
without schizophrenia.40 The reported frequency
of sexual dysfunction depends strongly on the
study methodology, and when no specific effort is
made to collect information regarding sexual
functioning, the rate of reported dysfunction is
universally low. In one study, only 10% of
patients spontaneously reported experiencing
sexual dysfunction. However, when specifically
surveyed, this complication was reported in up to
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Table 1. Studies That Measured Prolactin Levels in Patients Receiving Antipsychotic Drugs (continued)
Study Drugs (no. of patients) Study Description Prolactin Effects
Quetiapine (n=28), 6-wk, randomized, double-blind, After 6 wks of therapy, mean prolactin levels
haloperidol (n=24), placebo-controlled study in patients were 13.9 ng/ml in the quetiapine group
placebo (n=19)32 with schizophrenia; patients assigned (p=NS vs placebo), 28.8 ng/ml in the
to quetiapine 750 mg/day, haloperidol haloperidol group (p=0.0075 vs placebo),
12 mg/day, or placebo; prolactin levels and 14.7 ng/ml in the placebo group
measured after 6 wks of treatment; sex
distribution of patients not reported
Aripiprazole 4-wk, randomized, double-blind, Mean prolactin levels in both aripiprazole
(n=204;146 male, 58 female), placebo-controlled study in patients groups decreased slightly from baseline
haloperidol with schizophrenia; patients were (15-mg dose: 12.4 ng/ml; 30-mg dose:
(n=104; 68 male, 36 female), weaned from previous antipsychotic 12.3 ng/ml; p=NS vs placebo); mean
placebo and assigned to aripiprazole 15 mg prolactin level in haloperidol group
(n=106; 74 male, 32 female)33 (n=102) or 30 mg (n=102), haloperidol increased from a baseline of 15.7 ng/ml
10 mg, or placebo; prolactin levels to 38.2 ng/ml (p<0.001 vs placebo),
measured at baseline and at last no significant change in mean prolactin
study visit level in placebo group (11.2 ng/ml)
NS= not significant
aDoses were expressed as chlorpromazine equivalents.
ANTIPSYCHOTIC-INDUCED HYPERPROLACTINEMIA Bostwick et al
60% of patients treated with first-generation
antipsychotics and risperidone, and frequencies
of reported difficulties with orgasm and libido
were similar for women and men.41 Although it
is clear that hyperprolactinemia can cause sexual
dysfunction, it is certainly not the only possible
cause in many patients who are taking anti-
psychotics. Other pharmacologic effects of many
antipsychotics, such as -blockade or agonist or
antagonist effects on serotonin receptors, may
also affect sexual functioning. Consequently, the
rates of sexual dysfunction (loss of libido,
orgasmic difficulties, and erectile dysfunction)
are less likely to be correlated directly with
prolactin levels. One study found that the odds
ratio (compared with olanzapine) for loss of
libido was 1.46 with risperidone, 1.11 with
quetiapine, 1.27 with clozapine, and 1.73 with
oral first-generation antipsychotics.38 In patients
who had taken a specific antipsychotic for a 6-
month period, another study found that the
percentage of decreased sexual desire in men and
women taking haloperidol was 27.8%, olanzapine
36.5%, quetiapine 14.3%, and risperidone
38.8%.39
Bone Mineral Density
Patients receiving long-term antipsychotic
treatment causing elevations of prolactin levels
are at an increased risk for developing osteopenia
and osteoporosis, although many other factors
can affect BMD. Of interest, estrogen levels in
women do not always coincide with prolactin
levels. One group of authors obtained 17-
estradiol plasma levels in 75 women with
schizophrenia.30 Although prolactin levels were
significantly higher in the group taking oral first-
generation antipsychotics than in those taking
either clozapine or olanzapine, the 17- estradiol
levels were significantly lower in the olanzapine
group than in the clozapine and oral first-
generation antipsychotics groups. Overall, 57.3%
of the patients exhibited hypoestrogenism (< 30
pg/ml in follicular phase or < 100 pg/ml in the
periovulatory phase), which did not always
correlate with hyperprolactinemia.
Some researchers have hypothesized that
schizophrenia may be associated with hypo-
estrogenemia in women, regardless of drug
treatment.42, 43 In a study that evaluated 402
patients with schizophrenia treated with first-
generation antipsychotics or risperidone, 23.2%
of women and 31% of men had osteopenia (T
score ≤ -1), and prolactin level elevation was a
significant risk factor only in men.44 The authors
concluded that decreased BMD is highly
prevalent in this population. Moreover, in a
study of 55 patients with schizophrenia who were
treated with prolactin-elevating antipsychotics for
at least 10 years, the authors found reduced BMD
in 57% of men and 32% of postmenopausal
women.45 Using a primary care dataset in the
United Kingdom, a group of authors conducted
a case-control study identifying all patients who
had a fractured neck of the femur (or hip
fracture).”46 Each case was matched with two
control subjects for age, sex, and type of general
practice, for the risk of hip fracture. Their study
identified an association between hip fracture
and use of prolactin-elevating antipsychotic
drugs (odd ratio 2.6, 95% confidence interval
2.43–2.78). These studies indicate that hyper-
prolactinemia secondary to antipsychotic
treatment affects BMD in patients with
schizophrenia, but that decreased BMD may also
occur in the absence of elevated prolactin levels.
Breast and Pituitary Tumors
Some literature suggests a possible link
between prolactin level and breast cancer. Three
hundred six postmenopausal women with breast
cancer were compared with postmenopausal
control subjects on the basis of age, post-
menopausal hormone use, and timing and
method of blood collection, by using a nested
case-control study design.47 In this study,
postmenopausal women with higher prolactin
levels were at an increased risk for breast cancer
after other risk factors for breast cancer were
controlled. More specifically, women who had
prolactin levels in the upper quartile had twice
the risk for breast cancer compared with women
in the bottom quartile. Furthermore, findings
from a recently published review, citing seven
prospective studies, supports the link between
prolactin and an increased risk of breast cancer in
both pre- and postmenopausal women.48
Relating this to patients with psychiatric
disorders, a retrospective cohort study was
conducted with use of the Medicaid and
Pharmaceutical Assistance to the Aged and
Disabled databases in New Jersey that contained
52,819 women who were exposed and 55,289
women who were not exposed to dopamine
antagonists.49 The authors found a 16% increase
in the risk of breast cancer in patients exposed to
antipsychotic dopamine antagonists. Although
the potential role of confounding factors was
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cited as a limitation by the authors, they did find
a dose-response relationship indicating a higher
risk of breast cancer with increased dosages of
these drugs. In a medical record review, another
group found that the frequency of breast cancer
among 275 women older than 40 years who had
psychiatric disorders was 9.5 times higher than
the frequency reported in the general
population.50
A possible connection between elevated
prolactin levels and pituitary tumors has been
suggested by a recent pharmacovigilance study.51
Data from the FDA MedWatch program was
evaluated by using a Bayesian model to calculate
an adjusted reported ratio for pituitary tumor
risk. Risperidone was associated with the highest
adjusted reported ratio (18.7), but values were
also elevated for haloperidol (5.6), ziprasidone
(3.0), and olanzapine (2.3). The authors
concluded that their results do not necessarily
indicate a cause-and-effect relationship, but their
findings and the results from animal studies,
which found that hyperprolactinemia is
associated with pituitary tumors in rodents,
suggest that the relationship between elevated
prolactin levels and pituitary tumors deserves
further investigation.
Larger studies are needed to validate the
possible connections between
hyperprolactinemia and breast and/or pituitary
tumors, since many risk factors, aside from
hyperprolactinemia, play a role in the etiology of
these cancers.
Antipsychotic Drug Selection and Management
of the Effects of Hyperprolactinemia
Many different factors are considered in the
choice of an antipsychotic for a specific patient.
The major factor is whether the agent will
effectively treat the psychosis in that individual
patient. Unfortunately, there is no way of
determining a priori which drug will work in a
specific individual. Given this caveat, most
clinicians will select the antipsychotic that they
believe will be associated with the fewest
unacceptable adverse effects. Sometimes the
major issue will be weight gain or glucose
intolerance and other times it may be issues
associated with hyperprolactinemia such as
sexual dysfunction or menstrual disturbances.
If a major goal is to prevent antipsychotic-
induced hyperprolactinemia, appropriate drug
selection is key. The relative risk of antipsychotics
to cause elevated prolactin levels, based on an
extrapolation of available data, in approximate
order of highest to lowest propensity for causing
hyperprolactinemia is as follows: first-generation
antipsychotics, risperidone, paliperidone >
ziprasidone > olanzapine > quetiapine, clozapine
> aripiprazole. In addition, if prescribing a
highly potent D2-receptor–blocking agent, using
the lowest effective dose will help minimize the
risk of developing hyperprolactinemia.34 When
hyperprolactinemia causes significant effects,
possible options are changing to a prolactin-
sparing antipsychotic or reducing the dose.34
However, relapse is a risk with both of these
alternatives.1, 13, 52 An additional therapeutic
option is to add an antipsychotic that may
normalize prolactin levels, such as aripiprazole,
to the drug regimen.53 Subsequent to positive
anecdotal reports, a randomized, double-blind,
placebo-controlled study was conducted of
adjunctive treatment with aripiprazole added to
treatment of 54 patients with schizophrenia who
were stabilized with haloperidol 20–25 mg/day.54
Of the 26 patients receiving an aripiprazole dose
of 15 mg/day (increased to 30 mg/day after 4
wks), prolactin levels normalized in 84.6% of the
aripiprazole group (group by time interaction,
p<0.0001) and in only 3.6% of the placebo group
after 8 weeks. Prolactin-related adverse effects
also were significantly decreased in the group
receiving aripiprazole.
When it is necessary to use an antipsychotic
agent that is likely to cause hyperprolactinemia,
appropriate monitoring and management is
paramount. Specifically, clinicians should
inquire about menstrual disturbances in women,
changes in libido or galactorrhea in men and
women, and erectile or ejaculatory dysfunction in
men.52 If these symptoms are present, it would
be reasonable to obtain a baseline prolactin level.
After several weeks of antipsychotic treatment, a
follow-up prolactin level could be drawn for
comparison, at the same time and in the same
state (fasted or fed) as the baseline level.13
If an adverse effect that is distressing to the
patient is directly related to elevated prolactin
levels (such as amenorrhea or galactorrhea) and
cannot be managed by discontinuing the
offending antipsychotic, then treatment with a
dopamine agonist such as bromocriptine or
cabergoline could be considered. Cabergoline
has a longer elimination half-life and requires
only once- or twice-weekly administration, in
contrast to bromocriptine, which requires multiple
daily doses (unless slow-release formulations are
used). In some cases, cabergoline has caused less
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orthostatic hypotension, dizziness, headache, and
nasal congestion than bromocriptine.55 In
patients with psychiatric disorders, there is also a
risk for worsening of psychiatric symptoms when
a dopamine agonist is added to the drug regimen.
In women, combined oral contraceptives can be
used to resume menses and correct hypoestro-
genism.18, 56 In general, amenorrhea responds
better to treatment strategies than does
galactorrhea.1
If decreased libido, orgasmic difficulties, or
erectile dysfunction are suspected to be related to
an elevated prolactin level, then a corrective
measure should be started. In addition to the
effect that sexual dysfunction can have on a
patient’s quality of life, it is also likely to
negatively affect adherence to antipsychotic
therapy.57, 58 In general, patients should be
informed that antipsychotic drugs can be
associated with sexual dysfunction because
patients may be reluctant to discuss embarrassing
adverse effects, especially if they do not realize
that these may be drug induced. To help
circumvent this, counseling patients on potential
adverse effects is important, and clinicians should
regularly inquire whether the patient is
experiencing any untoward effects.13, 34, 52
Clinicians should also acknowledge that other
factors can increase the risk of sexual dysfunction
in patients with schizophrenia. Some of these
may include the social impact of schizophrenia,
as well as positive, negative, affective, and
cognitive symptoms.1, 41 If sexual dysfunction is
due to hyperprolactinemia, switching to a
prolactin-sparing antipsychotic will alleviate the
situation. In cases where this is not possible, a
dopamine agonist (bromocriptine or cabergoline)
might be added to the drug regimen.
Patients with schizophrenia are at risk for
reduced BMD secondary to schizophrenia itself
and drug-related factors.59–61 Factors unrelated to
antipsychotic treatment that put patients with
schizophrenia at risk for decreased BMD include
smoking, polydipsia resulting in excessive calcium
excretion, decreased exposure to sunlight,
excessive alcohol consumption, increased age,
poor nutrition, and inadequate exercise, and
possibly, the disease itself.56, 60 Obtaining baseline
BMD studies is recommended in all patients with
schizophrenia, as is monitoring prolactin levels
in patients treated with antipsychotic drugs when
early effects, such as decreased libido or
amenorrhea, appear.60 Repeat testing of prolactin
level in 3 months can be useful to monitor for
sustained elevation of prolactin.60
Likewise, BMD screening is recommended in
older men with schizophrenia who have been
treated with long-term first-generation anti-
psychotic therapy.16, 61 Although there is a
paucity of data surrounding who is at greatest
risk for developing osteoporosis and osteopenia,
some recommend providing education to patients
with schizophrenia to reduce their risk. Education
could include information on the importance of a
well-balanced diet with appropriate intake of
calcium and vitamin D, weight-bearing exercise,
smoking cessation, limiting caffeine and alcohol
intake, and ensuring adequate exposure to
sunlight.18, 46, 56 In addition to monitoring BMD,
bisphosphonates may be used as a preventive
measure in patients at high risk for osteoporosis.
In summary, if changing the drug dosage or
antipsychotic agent is not feasible, dopamine
agonists may be considered, especially in cases of
amenorrhea or galactorrhea. However, use of
these agents is somewhat controversial due to the
risk of worsening the patient’s psychiatric
symptoms.1, 11 Combined oral contraceptives
may also be considered in women with prolonged
amenorrhea who are at risk for developing
osteoporosis.1 It should be remembered that use
of oral contraceptives is not entirely benign and
may increase the risk of developing breast cancer,
as well as other conditions.
Conclusion
Both clinicians and patients must be aware of
the risk of antipsychotic-induced hyperprolactinemia
and its potential clinical implications. Health
care professionals should provide appropriate
education and vigilant monitoring of this drug-
induced complication. Hyperprolactinemia has
seriously devastating short- and long-term
consequences that can dramatically affect the
lives of patients who are treated with antipsychotic
drugs. Although first-generation antipsychotics
are most recognized for causing hyperprolactinemia,
clinicians must be aware that patients who are
treated with second-generation antipsychotics
remain at risk, especially those receiving risperi-
done or paliperidone. Moreover, monitoring for
hyperprolactinemia should be standardized
among clinicians. Additional research, however,
is needed to determine the long-term effects of
antipsychotic-induced hyperprolactinemia, as
growing numbers of children and adults are
being treated with these drugs.
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